| |
 |
ARTICLES 
|
|
| Positron emission tomography in the clinical evaluation of metastatic cancer |
| AJ Fischman |
|
JCO Mar 1 1996: 691–696.
[PDF]
|
 |
| Should we treat HER, too? |
| DF Hayes |
|
JCO Mar 1 1996: 697–699.
[PDF]
|
|
|
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil |
| |
M Findlay, H Young, D Cunningham, A Iveson, B Cronin, T Hickish, B Pratt, J Husband, M Flower, and R Ott |
| |
JCO Mar 1 1996: 700–708.
[Abstract]
[PDF]
|
|
|
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer |
| |
JA Conti, NE Kemeny, LB Saltz, Y Huang, WP Tong, TC Chou, M Sun, S Pulliam, and C Gonzalez |
| |
JCO Mar 1 1996: 709–715.
[Abstract]
[PDF]
|
|
|
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group |
| |
JR Zalcberg, D Cunningham, E Van Cutsem, E Francois, J Schornagel, A Adenis, M Green, A Iveson, M Azab, and I Seymour |
| |
JCO Mar 1 1996: 716–721.
[Abstract]
[PDF]
|
|
|
Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer |
| |
M Mohiuddin, E Chen, and N Ahmad |
| |
JCO Mar 1 1996: 722–728.
[Abstract]
[PDF]
|
|
|
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I- II study in previously untreated metastatic colorectal cancer patients |
| |
A Falcone, R Danesi, F Dargenio, E Pfanner, I Brunetti, M Del Tacca, AB Nethersell, and PF Conte |
| |
JCO Mar 1 1996: 729–736.
[Abstract]
[PDF]
|
|
|
Phase II study of weekly intravenous recombinant humanized anti- p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer |
| |
J Baselga, D Tripathy, J Mendelsohn, S Baughman, CC Benz, L Dantis, NT Sklarin, AD Seidman, CA Hudis, J Moore, PP Rosen, T Twaddell, IC Henderson, and L Norton |
| |
JCO Mar 1 1996: 737–744.
[Abstract]
[PDF]
|
|
|
Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study |
| |
PC Clahsen, CJ van de Velde, JP Julien, JL Floiras, T Delozier, FY Mignolet, and TM Sahmoud |
| |
JCO Mar 1 1996: 745–753.
[Abstract]
[PDF]
|
|
|
Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast |
| |
LJ Solin, J Kurtz, A Fourquet, R Amalric, A Recht, BA Bornstein, R Kuske, M Taylor, W Barrett, B Fowble, B Haffty, DJ Schultz, IT Yeh, B McCormick, and M McNeese |
| |
JCO Mar 1 1996: 754–763.
[Abstract]
[PDF]
|
|
|
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer |
| |
M Venturini, P Bruzzi, L Del Mastro, O Garrone, G Bertelli, M Guelfi, S Pastorino, R Rosso, and MR Sertoli |
| |
JCO Mar 1 1996: 764–773.
[Abstract]
[PDF]
|
|
|
Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer |
| |
JS Fisherman, KH Cowan, M Noone, A Denicoff, S Berg, D Poplack, F Balis, D Venzon, M McCabe, B Goldspiel, C Chow, FP Ognibene, and J O'Shaughnessy |
| |
JCO Mar 1 1996: 774–782.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer |
| |
MJ Kennedy, ML Zahurak, RC Donehower, DA Noe, S Sartorius, TL Chen, K Bowling, and EK Rowinsky |
| |
JCO Mar 1 1996: 783–791.
[Abstract]
[PDF]
|
|
|
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study |
| |
WP McGuire, JA Blessing, D Moore, SS Lentz, and G Photopulos |
| |
JCO Mar 1 1996: 792–795.
[Abstract]
[PDF]
|
|
|
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer |
| |
M Markman, T Hakes, R Barakat, J Curtin, L Almadrones, and W Hoskins |
| |
JCO Mar 1 1996: 796–799.
[Abstract]
[PDF]
|
|
|
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer |
| |
MJ Lind, S Ghazal-Aswad, L Gumbrell, K Fishwick, D Craigs, MJ Millward, NP Bailey, F Dore-Green, F Chapman, D Simmons, M Proctor, A Oakey, L Robson, I Middleton, E McCann, D Sinha, and AH Calvert |
| |
JCO Mar 1 1996: 800–805.
[Abstract]
[PDF]
|
|
|
Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine |
| |
BE Johnson, JD Bridges, M Sobczeck, J Gray, RI Linnoila, AF Gazdar, L Hankins, SM Steinberg, M Edison, JN Frame, H Pass, J Nesbitt, D Holden, JL Mulshine, E Glatstein, and DC Ihde |
| |
JCO Mar 1 1996: 806–813.
[Abstract]
[PDF]
|
|
|
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group |
| |
G Giaccone, A Ardizzoni, A Kirkpatrick, M Clerico, T Sahmoud, and N van Zandwijk |
| |
JCO Mar 1 1996: 814–820.
[Abstract]
[PDF]
|
|
|
Influence of age on the treatment of limited-stage small-cell lung cancer |
| |
LL Siu, FA Shepherd, N Murray, R Feld, J Pater, and B Zee |
| |
JCO Mar 1 1996: 821–828.
[Abstract]
[PDF]
|
|
|
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial |
| |
M Stahl, H Wilke, U Fink, M Stuschke, MK Walz, JR Siewert, M Molls, W Fett, HB Makoski, N Breuer, U Schmidt, W Niebel, H Sack, FW Eigler, and S Seeber |
| |
JCO Mar 1 1996: 829–837.
[Abstract]
[PDF]
|
|
|
Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials |
| |
S El-Sayed and N Nelson |
| |
JCO Mar 1 1996: 838–847.
[Abstract]
[PDF]
|
|
|
Tumor size and prognosis in aggressively treated osteosarcoma |
| |
P Bieling, N Rehan, P Winkler, K Helmke, R Maas, N Fuchs, S Bielack, U Heise, H Jurgens, J Treuner, R Romanowski, U Exner, R Kotz, and K Winkler |
| |
JCO Mar 1 1996: 848–858.
[Abstract]
[PDF]
|
|
|
Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma |
| |
PW Pisters, LB Harrison, DH Leung, JM Woodruff, ES Casper, and MF Brennan |
| |
JCO Mar 1 1996: 859–868.
[Abstract]
[PDF]
|
|
|
Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group |
| |
JM Coindre, P Terrier, NB Bui, F Bonichon, F Collin, V Le Doussal, AM Mandard, MO Vilain, J Jacquemier, H Duplay, X Sastre, C Barlier, M Henry-Amar, J Mace- Lesech, and G Contesso |
| |
JCO Mar 1 1996: 869–877.
[Abstract]
[PDF]
|
|
|
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a |
| |
P Soulie, P Ruffie, L Trandafir, I Monnet, A Tardivon, P Terrier, E Cvitkovic, T Le Chevalier, and JP Armand |
| |
JCO Mar 1 1996: 878–885.
[Abstract]
[PDF]
|
|
|
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma |
| |
JF Kuttesch, DM Parham, X Luo, WH Meyer, L Bowman, DN Shapiro, AS Pappo, WM Crist, WT Beck, and PJ Houghton |
| |
JCO Mar 1 1996: 886–900.
[Abstract]
[PDF]
|
|
|
Randomized trial of recombinant human granulocyte-macrophage colony- stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy |
| |
LH Wexler, L Weaver-McClure, SM Steinberg, J Jacobson, P Jarosinski, N Avila, PA Pizzo, and ME Horowitz |
| |
JCO Mar 1 1996: 901–910.
[Abstract]
[PDF]
|
|
|
High cure rate with a moderately intensive treatment regimen in non- high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group |
| |
AJ Veerman, K Hahlen, WA Kamps, EF Van Leeuwen, GA De Vaan, G Solbu, S Suciu, ER Van Wering, and A Van der Does-Van der Berg |
| |
JCO Mar 1 1996: 911–918.
[Abstract]
[PDF]
|
|
|
Predicting the risk of bacteremia in childen with fever and neutropenia |
| |
WR Rackoff, R Gonin, C Robinson, SG Kreissman, and PB Breitfeld |
| |
JCO Mar 1 1996: 919–924.
[Abstract]
[PDF]
|
|
|
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen |
| |
I Magrath, M Adde, A Shad, D Venzon, N Seibel, J Gootenberg, J Neely, C Arndt, M Nieder, E Jaffe, RA Wittes, and ID Horak |
| |
JCO Mar 1 1996: 925–934.
[Abstract]
[PDF]
|
|
|
Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine |
| |
M Weintraub, MA Adde, DJ Venzon, AT Shad, ID Horak, JE Neely, NL Seibel, J Gootenberg, C Arndt, ML Nieder, and IT Magrath |
| |
JCO Mar 1 1996: 935–940.
[Abstract]
[PDF]
|
|
|
CNS involvement in mantle-cell lymphoma |
| |
E Montserrat, F Bosch, A Lopez-Guillermo, F Graus, MJ Terol, E Campo, and C Rozman |
| |
JCO Mar 1 1996: 941–944.
[Abstract]
[PDF]
|
|
|
Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy |
| |
EM Bessell, F Graus, JA Punt, JL Firth, DT Hope, AJ Moloney, A Lopez-Guillermo, and S Villa |
| |
JCO Mar 1 1996: 945–954.
[Abstract]
[PDF]
|
|
|
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients |
| |
PL Zinzani, M Bendandi, M Martelli, B Falini, E Sabattini, S Amadori, F Gherlinzoni, MF Martelli, F Mandelli, S Tura, and SA Pileri |
| |
JCO Mar 1 1996: 955–962.
[Abstract]
[PDF]
|
|
|
Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-artificial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation |
| |
M Poetsch, K Weber-Matthiesen, HJ Plendl, W Grote, and B Schlegelberger |
| |
JCO Mar 1 1996: 963–969.
[Abstract]
[PDF]
|
|
|
When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood |
| |
C Elliott, DM Samson, S Armitage, MP Lyttelton, D McGuigan, R Hargreaves, C Giles, G Abrahamson, Z Abboudi, M Brennan, and EJ Kanfer |
| |
JCO Mar 1 1996: 970–973.
[Abstract]
[PDF]
|
|
|
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229 |
| |
MR Modiano, P Villar-Werstler, J Crowley, and SE Salmon |
| |
JCO Mar 1 1996: 974–977.
[Abstract]
[PDF]
|
|
|
Pharmacokinetic study of oral and bolus intravenous 2- chlorodeoxyadenosine in patients with malignancy |
| |
A Saven, WK Cheung, I Smith, M Moyer, T Johannsen, E Rose, R Gollard, M Kosty, WE Miller, and LD Piro |
| |
JCO Mar 1 1996: 978–983.
[Abstract]
[PDF]
|
|
|
Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials |
| |
NK Aaronson, E Visser-Pol, GH Leenhouts, MJ Muller, AC van der Schot, FS van Dam, RB Keus, CC Koning, WW ten Bokkel Huinink, JA van Dongen, and R Dubbelman |
| |
JCO Mar 1 1996: 984–996.
[Abstract]
[PDF]
|
|
|
Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? |
| |
JA Roy, CA Sawka, and KI Pritchard |
| |
JCO Mar 1 1996: 997–1006.
[Abstract]
[PDF]
|
|
|
Chemotherapy in malignant pleural mesothelioma. A review |
| |
ST Ong and NJ Vogelzang |
| |
JCO Mar 1 1996: 1007–1017.
[Abstract]
[PDF]
|
|
|
Tamoxifen-associated eye disease. A review |
| |
SG Nayfield and MB Gorin |
| |
JCO Mar 1 1996: 1018–1026.
[Abstract]
[PDF]
|
|
| Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients |
| B Fisher |
|
JCO Mar 1 1996: 1027–1039.
[PDF]
|
|
| Medical oncology for the general internal medicine trainee. American Society of Clinical Oncology |
|
|
JCO Mar 1 1996: 1040–1041.
[PDF]
|
|
| Paclitaxel hypersensitivity revisited |
| DM Essayan, A Kagey-Sobotka, and LM Lichtenstein |
|
JCO Mar 1 1996: 1042a.
[PDF]
|
|
| Strange bedfellows |
| SM Grunberg |
|
JCO Mar 1 1996: 1042b–1043.
[PDF]
|
|
| Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma |
| I Celik, A Kars, E Ozyar, G Tekuzman, L Atahan, and D Firat |
|
JCO Mar 1 1996: 1043–1044.
[PDF]
|
|
